Learn what you need to know about early-stage prostate cancer, from risk factors to treatment options and how to tackle their side effects. Prostate cancer: 1 in 8 men in the United States will be ...

Vipul R. Patel, MD, FACS, is a board-certified urologic surgeon, medical director of the Global Robotics Institute at AdventHealth, and medical director of urologic oncology at AdventHealth Cancer ...

A minimally-invasive treatment using MRI and transurethral ultrasound instead of surgery or radiation is effective in treating prostate cancer, according to new research to be presented at the Society ...

Prostate cancer is the second most common cancer in men worldwide. Researchers have investigated a new strategy for the development of treatment options that not only slow tumor growth, but also ...

HAMPTON ROADS, Va. — Next step: getting my prostate cancer treated! Last month I shared I was diagnosed with it, in fact, one area is considered a high-grade cancer which has narrowed by options for ...

An expert explains the significance of the recent approval of Xtandi for non-metastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk ...

Despite previous research pointing to a substantial increase in global prostate cancer mortality in the future, Isaac Y. Kim, ...

Erleada showed a 23% reduction in mortality compared to Xtandi in real-world settings, offering potential survival benefits for metastatic castration-sensitive prostate cancer patients. Real-world ...

Patients say the difference it makes is amazing. A state-of-the-art laser prostate reduction operation is now being successfully delivered in the county as a day case procedure. HOLEP, or Holmium ...

Prostate cancer is the second most common cancer in men worldwide. Despite medical advances in recent years, this type of tumour is still responsible for one in eight male cancer deaths in Austria ...